Revenue -- $14.5 million in the fiscal fourth quarter ended Sept. 30, 2025, up 11% year-over-year. Gross margin -- 37% in the ...

Hello, everyone, and thank you for joining us to review CSPi's Fiscal 2025 First Quarter Financial Results, as well as recent ...

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...

A high-profile acquisition by a global cybersecurity leader could help signal renewed confidence in Israeli cyber startups.

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the, " Anti-Jamming ...

New artificial intelligence-enabled health wearable devices and clinical decision support software will not face U.S. Food ...